Related Experiment Video

Updated: May 1, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer

Naoki Kaneto1, Satoru Yokoyama, Yoshihiro Hayakawa

  • 1Division of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, Toyama, Japan.

Cancer Science
|April 23, 2014
PubMed

Insights

Targeting the RAC1 pathway can overcome resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC). RAC1 inhibition suppressed tumor growth and migration, even in drug-resistant NSCLC cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) offer clinical benefits for non-small-cell lung cancer (NSCLC).
  • Acquired drug resistance limits the long-term efficacy of EGFR-TKI therapy in NSCLC patients.
  • EGFR signaling plays a role in NSCLC cell migration and progression.

Purpose of the Study:

  • To investigate the role of the RAC1 pathway in EGFR-mediated NSCLC progression.
  • To determine if targeting RAC1 can overcome resistance to EGFR-TKIs in NSCLC.

Main Methods:

  • Gene silencing of RAC1 and induction of constitutive active RAC1 in EGFR-mutant NSCLC cells.
  • In vitro and in vivo assays to assess cell migration, lamellipodia formation, and tumor growth.
  • Evaluation of RAC1 inhibition's effect on gefitinib-resistant NSCLC cells.

Main Results:

  • RAC1 pathway is crucial for EGFR-mediated NSCLC cell migration and lamellipodia formation.
  • RAC1 inhibition suppressed migration and growth of EGFR-mutant NSCLC cells in vitro and in vivo.
  • Suppression of tumor growth by RAC1 inhibition occurred independently of MEK or PI3K pathways, even in gefitinib-resistant cells.

Conclusions:

  • The RAC1 pathway is a key mediator of NSCLC progression and resistance to EGFR-TKIs.
  • Targeting the RAC1 pathway presents a promising therapeutic strategy to overcome EGFR-TKI resistance in NSCLC.
  • This approach offers a new avenue for controlling cancer progression in NSCLC patients resistant to current therapies.
Keywords:
Epidermal growth factor receptor tyrosine kinase inhibitorsRAC1gefitinibmigrationnon-small-cell lung cancer

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

9.5K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689